nodes	percent_of_prediction	percent_of_DWPC	metapath
Phenylpropanolamine—Phentermine—obesity	0.174	0.529	CrCtD
Phenylpropanolamine—Methamphetamine—obesity	0.155	0.471	CrCtD
Phenylpropanolamine—DRD1—obesity	0.0513	0.369	CbGaD
Phenylpropanolamine—ADRB1—obesity	0.0476	0.343	CbGaD
Phenylpropanolamine—ADRB2—obesity	0.0401	0.288	CbGaD
Phenylpropanolamine—Tranylcypromine—Phendimetrazine—obesity	0.0253	0.115	CrCrCtD
Phenylpropanolamine—SLC6A3—Diethylpropion—obesity	0.0206	0.0876	CbGbCtD
Phenylpropanolamine—MAOA—Phentermine—obesity	0.0175	0.0744	CbGbCtD
Phenylpropanolamine—SLC6A3—Sibutramine—obesity	0.0156	0.0664	CbGbCtD
Phenylpropanolamine—SLC6A3—Phendimetrazine—obesity	0.0156	0.0664	CbGbCtD
Phenylpropanolamine—SLC6A2—Diethylpropion—obesity	0.0151	0.0641	CbGbCtD
Phenylpropanolamine—MAOA—Methamphetamine—obesity	0.014	0.0594	CbGbCtD
Phenylpropanolamine—Tranylcypromine—Phentermine—obesity	0.013	0.0592	CrCrCtD
Phenylpropanolamine—SLC6A3—Phentermine—obesity	0.0118	0.0503	CbGbCtD
Phenylpropanolamine—SLC6A3—Benzphetamine—obesity	0.0118	0.0503	CbGbCtD
Phenylpropanolamine—SLC6A2—Phendimetrazine—obesity	0.0114	0.0486	CbGbCtD
Phenylpropanolamine—SLC6A2—Sibutramine—obesity	0.0114	0.0486	CbGbCtD
Phenylpropanolamine—Ephedrine—Phentermine—obesity	0.0103	0.047	CrCrCtD
Phenylpropanolamine—Pseudoephedrine—Phentermine—obesity	0.0103	0.047	CrCrCtD
Phenylpropanolamine—SLC6A3—Bupropion—obesity	0.0101	0.0428	CbGbCtD
Phenylpropanolamine—ADRA1A—Phendimetrazine—obesity	0.00988	0.042	CbGbCtD
Phenylpropanolamine—SLC6A3—Methamphetamine—obesity	0.00946	0.0402	CbGbCtD
Phenylpropanolamine—Pseudoephedrine—Methamphetamine—obesity	0.00922	0.0419	CrCrCtD
Phenylpropanolamine—Ephedrine—Methamphetamine—obesity	0.00922	0.0419	CrCrCtD
Phenylpropanolamine—Phenol—Phentermine—obesity	0.00902	0.041	CrCrCtD
Phenylpropanolamine—SLC6A2—Benzphetamine—obesity	0.00866	0.0368	CbGbCtD
Phenylpropanolamine—SLC6A2—Phentermine—obesity	0.00866	0.0368	CbGbCtD
Phenylpropanolamine—Phenelzine—Phentermine—obesity	0.00865	0.0393	CrCrCtD
Phenylpropanolamine—Amphetamine—Diethylpropion—obesity	0.00825	0.0375	CrCrCtD
Phenylpropanolamine—Dextroamphetamine—Diethylpropion—obesity	0.00825	0.0375	CrCrCtD
Phenylpropanolamine—Phenol—Methamphetamine—obesity	0.00804	0.0365	CrCrCtD
Phenylpropanolamine—Methamphetamine—Diethylpropion—obesity	0.00801	0.0364	CrCrCtD
Phenylpropanolamine—ADRA2A—Benzphetamine—obesity	0.00781	0.0332	CbGbCtD
Phenylpropanolamine—Benzyl alcohol—Phentermine—obesity	0.00774	0.0352	CrCrCtD
Phenylpropanolamine—Phenelzine—Methamphetamine—obesity	0.00771	0.035	CrCrCtD
Phenylpropanolamine—ADRA1A—Benzphetamine—obesity	0.00749	0.0318	CbGbCtD
Phenylpropanolamine—Phentermine—Methamphetamine—obesity	0.00742	0.0337	CrCrCtD
Phenylpropanolamine—SLC6A2—Bupropion—obesity	0.00737	0.0313	CbGbCtD
Phenylpropanolamine—SLC6A2—Methamphetamine—obesity	0.00693	0.0294	CbGbCtD
Phenylpropanolamine—Benzyl alcohol—Methamphetamine—obesity	0.0069	0.0313	CrCrCtD
Phenylpropanolamine—Amphetamine—Phentermine—obesity	0.00681	0.0309	CrCrCtD
Phenylpropanolamine—Dextroamphetamine—Phentermine—obesity	0.00681	0.0309	CrCrCtD
Phenylpropanolamine—Methamphetamine—Phentermine—obesity	0.00661	0.03	CrCrCtD
Phenylpropanolamine—L-Phenylalanine—Diethylpropion—obesity	0.00627	0.0285	CrCrCtD
Phenylpropanolamine—ADRA2A—Methamphetamine—obesity	0.00624	0.0265	CbGbCtD
Phenylpropanolamine—Dextroamphetamine—Methamphetamine—obesity	0.00607	0.0276	CrCrCtD
Phenylpropanolamine—Amphetamine—Methamphetamine—obesity	0.00607	0.0276	CrCrCtD
Phenylpropanolamine—L-Phenylalanine—Phentermine—obesity	0.00518	0.0235	CrCrCtD
Phenylpropanolamine—Amphetamine—Benzphetamine—obesity	0.00481	0.0219	CrCrCtD
Phenylpropanolamine—Dextroamphetamine—Benzphetamine—obesity	0.00481	0.0219	CrCrCtD
Phenylpropanolamine—Methamphetamine—Benzphetamine—obesity	0.00467	0.0212	CrCrCtD
Phenylpropanolamine—L-Phenylalanine—Methamphetamine—obesity	0.00462	0.021	CrCrCtD
Phenylpropanolamine—CYP1A2—Phentermine—obesity	0.00315	0.0134	CbGbCtD
Phenylpropanolamine—CYP1A2—Bupropion—obesity	0.00268	0.0114	CbGbCtD
Phenylpropanolamine—CYP1A2—Cimetidine—obesity	0.00197	0.00836	CbGbCtD
Phenylpropanolamine—Dysphoria—Methamphetamine—obesity	0.00187	0.0524	CcSEcCtD
Phenylpropanolamine—Dysphoria—Phentermine—obesity	0.00134	0.0377	CcSEcCtD
Phenylpropanolamine—Dysphoria—Diethylpropion—obesity	0.00117	0.0328	CcSEcCtD
Phenylpropanolamine—SLC6A2—sympathetic nervous system—obesity	0.00108	0.168	CbGeAlD
Phenylpropanolamine—Serotonin syndrome—Sibutramine—obesity	0.000734	0.0206	CcSEcCtD
Phenylpropanolamine—SLC6A2—autonomic nervous system—obesity	0.000729	0.113	CbGeAlD
Phenylpropanolamine—Blood pressure increased—Phendimetrazine—obesity	0.000709	0.0199	CcSEcCtD
Phenylpropanolamine—Euphoric mood—Methamphetamine—obesity	0.000693	0.0195	CcSEcCtD
Phenylpropanolamine—Psychotic disorder—Methamphetamine—obesity	0.000572	0.0161	CcSEcCtD
Phenylpropanolamine—Liver injury—Cimetidine—obesity	0.00057	0.016	CcSEcCtD
Phenylpropanolamine—Psychotic disorder—Benzphetamine—obesity	0.000551	0.0155	CcSEcCtD
Phenylpropanolamine—Dyskinesia—Diethylpropion—obesity	0.000537	0.0151	CcSEcCtD
Phenylpropanolamine—Dysphoria—Bupropion—obesity	0.000517	0.0145	CcSEcCtD
Phenylpropanolamine—Blood pressure increased—Diethylpropion—obesity	0.000504	0.0142	CcSEcCtD
Phenylpropanolamine—Psychotic disorder—Phendimetrazine—obesity	0.000503	0.0141	CcSEcCtD
Phenylpropanolamine—Euphoric mood—Phentermine—obesity	0.000498	0.014	CcSEcCtD
Phenylpropanolamine—Euphoric mood—Diethylpropion—obesity	0.000433	0.0122	CcSEcCtD
Phenylpropanolamine—Psychotic disorder—Phentermine—obesity	0.000411	0.0115	CcSEcCtD
Phenylpropanolamine—SLC6A3—hindbrain—obesity	0.000381	0.0589	CbGeAlD
Phenylpropanolamine—Psychotic disorder—Diethylpropion—obesity	0.000357	0.01	CcSEcCtD
Phenylpropanolamine—Psychotic disorder—Cimetidine—obesity	0.00034	0.00956	CcSEcCtD
Phenylpropanolamine—Urinary retention—Cimetidine—obesity	0.000331	0.00931	CcSEcCtD
Phenylpropanolamine—Flushing—Phendimetrazine—obesity	0.00033	0.00929	CcSEcCtD
Phenylpropanolamine—Tremor—Methamphetamine—obesity	0.00033	0.00929	CcSEcCtD
Phenylpropanolamine—Agitation—Methamphetamine—obesity	0.000324	0.00911	CcSEcCtD
Phenylpropanolamine—Tremor—Benzphetamine—obesity	0.000319	0.00895	CcSEcCtD
Phenylpropanolamine—Agitation—Benzphetamine—obesity	0.000313	0.00878	CcSEcCtD
Phenylpropanolamine—Phenelzine—GPT—obesity	0.000307	0.249	CrCbGaD
Phenylpropanolamine—Vision blurred—Phendimetrazine—obesity	0.000292	0.00821	CcSEcCtD
Phenylpropanolamine—Tremor—Phendimetrazine—obesity	0.00029	0.00816	CcSEcCtD
Phenylpropanolamine—Hallucination—Phentermine—obesity	0.00029	0.00814	CcSEcCtD
Phenylpropanolamine—ADRA1A—hindbrain—obesity	0.000286	0.0442	CbGeAlD
Phenylpropanolamine—Agitation—Phendimetrazine—obesity	0.000285	0.008	CcSEcCtD
Phenylpropanolamine—MAOA—hindbrain—obesity	0.000283	0.0438	CbGeAlD
Phenylpropanolamine—Drowsiness—Diethylpropion—obesity	0.000282	0.00793	CcSEcCtD
Phenylpropanolamine—Tachycardia—Methamphetamine—obesity	0.000281	0.00789	CcSEcCtD
Phenylpropanolamine—Tachycardia—Benzphetamine—obesity	0.000271	0.00761	CcSEcCtD
Phenylpropanolamine—Drowsiness—Cimetidine—obesity	0.000268	0.00754	CcSEcCtD
Phenylpropanolamine—Liver injury—Bupropion—obesity	0.000266	0.00746	CcSEcCtD
Phenylpropanolamine—Insomnia—Methamphetamine—obesity	0.00026	0.00732	CcSEcCtD
Phenylpropanolamine—Blood pressure increased—Sibutramine—obesity	0.000256	0.0072	CcSEcCtD
Phenylpropanolamine—Insomnia—Benzphetamine—obesity	0.000251	0.00705	CcSEcCtD
Phenylpropanolamine—Tension—Phentermine—obesity	0.000249	0.00699	CcSEcCtD
Phenylpropanolamine—Tachycardia—Phendimetrazine—obesity	0.000247	0.00694	CcSEcCtD
Phenylpropanolamine—Amphetamine—CARTPT—obesity	0.000246	0.2	CrCbGaD
Phenylpropanolamine—Constipation—Methamphetamine—obesity	0.000246	0.00692	CcSEcCtD
Phenylpropanolamine—Nervousness—Phentermine—obesity	0.000246	0.00692	CcSEcCtD
Phenylpropanolamine—Hallucination—Cimetidine—obesity	0.00024	0.00674	CcSEcCtD
Phenylpropanolamine—Dyskinesia—Bupropion—obesity	0.000238	0.00668	CcSEcCtD
Phenylpropanolamine—Tremor—Phentermine—obesity	0.000237	0.00667	CcSEcCtD
Phenylpropanolamine—Agitation—Phentermine—obesity	0.000233	0.00654	CcSEcCtD
Phenylpropanolamine—SLC6A3—respiratory system—obesity	0.000232	0.036	CbGeAlD
Phenylpropanolamine—Insomnia—Phendimetrazine—obesity	0.000229	0.00643	CcSEcCtD
Phenylpropanolamine—Coordination abnormal—Bupropion—obesity	0.000228	0.00639	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Diethylpropion—obesity	0.000226	0.00636	CcSEcCtD
Phenylpropanolamine—Hepatocellular injury—Bupropion—obesity	0.000223	0.00628	CcSEcCtD
Phenylpropanolamine—Blood pressure increased—Bupropion—obesity	0.000223	0.00628	CcSEcCtD
Phenylpropanolamine—Euphoric mood—Sibutramine—obesity	0.00022	0.00619	CcSEcCtD
Phenylpropanolamine—Constipation—Phendimetrazine—obesity	0.000216	0.00608	CcSEcCtD
Phenylpropanolamine—Tension—Diethylpropion—obesity	0.000216	0.00608	CcSEcCtD
Phenylpropanolamine—Nervousness—Diethylpropion—obesity	0.000214	0.00602	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Methamphetamine—obesity	0.000212	0.00596	CcSEcCtD
Phenylpropanolamine—Vision blurred—Diethylpropion—obesity	0.000208	0.00584	CcSEcCtD
Phenylpropanolamine—Tremor—Diethylpropion—obesity	0.000207	0.0058	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Benzphetamine—obesity	0.000204	0.00575	CcSEcCtD
Phenylpropanolamine—Agitation—Diethylpropion—obesity	0.000203	0.00569	CcSEcCtD
Phenylpropanolamine—Tachycardia—Phentermine—obesity	0.000202	0.00567	CcSEcCtD
Phenylpropanolamine—Phenelzine—AOC3—obesity	0.000198	0.161	CrCbGaD
Phenylpropanolamine—Agitation—Cimetidine—obesity	0.000193	0.00542	CcSEcCtD
Phenylpropanolamine—Euphoric mood—Bupropion—obesity	0.000192	0.0054	CcSEcCtD
Phenylpropanolamine—Dizziness—Methamphetamine—obesity	0.00019	0.00535	CcSEcCtD
Phenylpropanolamine—SLC6A2—respiratory system—obesity	0.000188	0.029	CbGeAlD
Phenylpropanolamine—Insomnia—Phentermine—obesity	0.000187	0.00526	CcSEcCtD
Phenylpropanolamine—Anxiety—Diethylpropion—obesity	0.000187	0.00526	CcSEcCtD
Phenylpropanolamine—Dizziness—Benzphetamine—obesity	0.000184	0.00516	CcSEcCtD
Phenylpropanolamine—MAOA—islet of Langerhans—obesity	0.000183	0.0283	CbGeAlD
Phenylpropanolamine—Psychotic disorder—Sibutramine—obesity	0.000182	0.00511	CcSEcCtD
Phenylpropanolamine—Anxiety—Cimetidine—obesity	0.000178	0.005	CcSEcCtD
Phenylpropanolamine—Urinary retention—Sibutramine—obesity	0.000177	0.00497	CcSEcCtD
Phenylpropanolamine—Constipation—Phentermine—obesity	0.000177	0.00497	CcSEcCtD
Phenylpropanolamine—Tachycardia—Diethylpropion—obesity	0.000176	0.00493	CcSEcCtD
Phenylpropanolamine—Ataxia—Sibutramine—obesity	0.000175	0.00492	CcSEcCtD
Phenylpropanolamine—MAOA—respiratory system—obesity	0.000173	0.0267	CbGeAlD
Phenylpropanolamine—Confusional state—Cimetidine—obesity	0.000173	0.00485	CcSEcCtD
Phenylpropanolamine—ADRB1—cardiovascular system—obesity	0.000169	0.0261	CbGeAlD
Phenylpropanolamine—Dizziness—Phendimetrazine—obesity	0.000167	0.0047	CcSEcCtD
Phenylpropanolamine—Tachycardia—Cimetidine—obesity	0.000167	0.00469	CcSEcCtD
Phenylpropanolamine—Nausea—Benzphetamine—obesity	0.000165	0.00463	CcSEcCtD
Phenylpropanolamine—Insomnia—Diethylpropion—obesity	0.000163	0.00457	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Diethylpropion—obesity	0.00016	0.00451	CcSEcCtD
Phenylpropanolamine—Somnolence—Diethylpropion—obesity	0.00016	0.00449	CcSEcCtD
Phenylpropanolamine—Psychotic disorder—Bupropion—obesity	0.000158	0.00445	CcSEcCtD
Phenylpropanolamine—Irritability—Bupropion—obesity	0.000155	0.00435	CcSEcCtD
Phenylpropanolamine—Urinary retention—Bupropion—obesity	0.000154	0.00433	CcSEcCtD
Phenylpropanolamine—Constipation—Diethylpropion—obesity	0.000154	0.00432	CcSEcCtD
Phenylpropanolamine—Ataxia—Bupropion—obesity	0.000153	0.00429	CcSEcCtD
Phenylpropanolamine—Somnolence—Cimetidine—obesity	0.000152	0.00428	CcSEcCtD
Phenylpropanolamine—Dyskinesia—Topiramate—obesity	0.000151	0.00426	CcSEcCtD
Phenylpropanolamine—Nausea—Phendimetrazine—obesity	0.00015	0.00422	CcSEcCtD
Phenylpropanolamine—ADRB1—adipose tissue—obesity	0.000149	0.023	CbGeAlD
Phenylpropanolamine—Feeling abnormal—Diethylpropion—obesity	0.000148	0.00417	CcSEcCtD
Phenylpropanolamine—Constipation—Cimetidine—obesity	0.000146	0.00411	CcSEcCtD
Phenylpropanolamine—MAOA—adrenal cortex—obesity	0.000145	0.0224	CbGeAlD
Phenylpropanolamine—Coordination abnormal—Topiramate—obesity	0.000145	0.00407	CcSEcCtD
Phenylpropanolamine—CYP1A2—respiratory system—obesity	0.000144	0.0223	CbGeAlD
Phenylpropanolamine—Feeling abnormal—Cimetidine—obesity	0.000141	0.00396	CcSEcCtD
Phenylpropanolamine—ADRA2A—islet of Langerhans—obesity	0.00014	0.0217	CbGeAlD
Phenylpropanolamine—Dizziness—Phentermine—obesity	0.000137	0.00384	CcSEcCtD
Phenylpropanolamine—ADRA1A—cardiovascular system—obesity	0.000134	0.0207	CbGeAlD
Phenylpropanolamine—MAOA—cardiovascular system—obesity	0.000132	0.0205	CbGeAlD
Phenylpropanolamine—Vomiting—Phentermine—obesity	0.000131	0.00369	CcSEcCtD
Phenylpropanolamine—Rash—Phentermine—obesity	0.00013	0.00366	CcSEcCtD
Phenylpropanolamine—Dermatitis—Phentermine—obesity	0.00013	0.00366	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Cimetidine—obesity	0.000126	0.00354	CcSEcCtD
Phenylpropanolamine—Nausea—Phentermine—obesity	0.000123	0.00345	CcSEcCtD
Phenylpropanolamine—Euphoric mood—Topiramate—obesity	0.000122	0.00344	CcSEcCtD
Phenylpropanolamine—Dizziness—Diethylpropion—obesity	0.000119	0.00334	CcSEcCtD
Phenylpropanolamine—ADRA1A—adipose tissue—obesity	0.000118	0.0182	CbGeAlD
Phenylpropanolamine—MAOA—pituitary gland—obesity	0.000117	0.0181	CbGeAlD
Phenylpropanolamine—MAOA—adipose tissue—obesity	0.000117	0.0181	CbGeAlD
Phenylpropanolamine—ADRB1—endocrine gland—obesity	0.000116	0.0179	CbGeAlD
Phenylpropanolamine—Arrhythmia—Sibutramine—obesity	0.000115	0.00323	CcSEcCtD
Phenylpropanolamine—Vomiting—Diethylpropion—obesity	0.000114	0.00321	CcSEcCtD
Phenylpropanolamine—SLC6A2—adrenal gland—obesity	0.000114	0.0176	CbGeAlD
Phenylpropanolamine—Rash—Diethylpropion—obesity	0.000113	0.00319	CcSEcCtD
Phenylpropanolamine—Dermatitis—Diethylpropion—obesity	0.000113	0.00318	CcSEcCtD
Phenylpropanolamine—Dizziness—Cimetidine—obesity	0.000113	0.00318	CcSEcCtD
Phenylpropanolamine—Hallucination—Bupropion—obesity	0.000112	0.00314	CcSEcCtD
Phenylpropanolamine—Tension—Sibutramine—obesity	0.00011	0.00309	CcSEcCtD
Phenylpropanolamine—MAOA—digestive system—obesity	0.00011	0.017	CbGeAlD
Phenylpropanolamine—Vision blurred—Orlistat—obesity	0.000109	0.00307	CcSEcCtD
Phenylpropanolamine—Nervousness—Sibutramine—obesity	0.000109	0.00306	CcSEcCtD
Phenylpropanolamine—Vomiting—Cimetidine—obesity	0.000109	0.00306	CcSEcCtD
Phenylpropanolamine—Rash—Cimetidine—obesity	0.000108	0.00303	CcSEcCtD
Phenylpropanolamine—Dermatitis—Cimetidine—obesity	0.000108	0.00303	CcSEcCtD
Phenylpropanolamine—Nausea—Diethylpropion—obesity	0.000107	0.003	CcSEcCtD
Phenylpropanolamine—ADRA1A—adrenal gland—obesity	0.000106	0.0163	CbGeAlD
Phenylpropanolamine—Vision blurred—Sibutramine—obesity	0.000106	0.00297	CcSEcCtD
Phenylpropanolamine—Tremor—Sibutramine—obesity	0.000105	0.00295	CcSEcCtD
Phenylpropanolamine—MAOA—adrenal gland—obesity	0.000105	0.0162	CbGeAlD
Phenylpropanolamine—Flushing—Bupropion—obesity	0.000104	0.00293	CcSEcCtD
Phenylpropanolamine—Agitation—Sibutramine—obesity	0.000103	0.00289	CcSEcCtD
Phenylpropanolamine—Nausea—Cimetidine—obesity	0.000102	0.00286	CcSEcCtD
Phenylpropanolamine—Psychotic disorder—Topiramate—obesity	0.000101	0.00284	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Bupropion—obesity	0.0001	0.00282	CcSEcCtD
Phenylpropanolamine—Irritability—Topiramate—obesity	9.86e-05	0.00277	CcSEcCtD
Phenylpropanolamine—SLC6A2—endocrine gland—obesity	9.85e-05	0.0152	CbGeAlD
Phenylpropanolamine—Urinary retention—Topiramate—obesity	9.83e-05	0.00276	CcSEcCtD
Phenylpropanolamine—Anxiety—Orlistat—obesity	9.82e-05	0.00276	CcSEcCtD
Phenylpropanolamine—Ataxia—Topiramate—obesity	9.72e-05	0.00273	CcSEcCtD
Phenylpropanolamine—Tension—Bupropion—obesity	9.59e-05	0.00269	CcSEcCtD
Phenylpropanolamine—Anxiety—Sibutramine—obesity	9.51e-05	0.00267	CcSEcCtD
Phenylpropanolamine—Nervousness—Bupropion—obesity	9.49e-05	0.00267	CcSEcCtD
Phenylpropanolamine—Confusional state—Sibutramine—obesity	9.22e-05	0.00259	CcSEcCtD
Phenylpropanolamine—Vision blurred—Bupropion—obesity	9.21e-05	0.00259	CcSEcCtD
Phenylpropanolamine—CYP1A2—digestive system—obesity	9.17e-05	0.0142	CbGeAlD
Phenylpropanolamine—ADRA1A—endocrine gland—obesity	9.16e-05	0.0142	CbGeAlD
Phenylpropanolamine—Tremor—Bupropion—obesity	9.15e-05	0.00257	CcSEcCtD
Phenylpropanolamine—MAOA—endocrine gland—obesity	9.08e-05	0.014	CbGeAlD
Phenylpropanolamine—ADRA2A—pituitary gland—obesity	8.99e-05	0.0139	CbGeAlD
Phenylpropanolamine—Agitation—Bupropion—obesity	8.98e-05	0.00252	CcSEcCtD
Phenylpropanolamine—ADRA2A—adipose tissue—obesity	8.95e-05	0.0139	CbGeAlD
Phenylpropanolamine—Tachycardia—Sibutramine—obesity	8.93e-05	0.00251	CcSEcCtD
Phenylpropanolamine—Insomnia—Orlistat—obesity	8.55e-05	0.0024	CcSEcCtD
Phenylpropanolamine—Hypotension—Sibutramine—obesity	8.55e-05	0.0024	CcSEcCtD
Phenylpropanolamine—Anxiety—Bupropion—obesity	8.29e-05	0.00233	CcSEcCtD
Phenylpropanolamine—Insomnia—Sibutramine—obesity	8.27e-05	0.00232	CcSEcCtD
Phenylpropanolamine—ADRA1A—liver—obesity	8.26e-05	0.0128	CbGeAlD
Phenylpropanolamine—MAOA—liver—obesity	8.18e-05	0.0127	CbGeAlD
Phenylpropanolamine—Dyspnoea—Sibutramine—obesity	8.15e-05	0.00229	CcSEcCtD
Phenylpropanolamine—Somnolence—Sibutramine—obesity	8.13e-05	0.00228	CcSEcCtD
Phenylpropanolamine—Confusional state—Bupropion—obesity	8.04e-05	0.00226	CcSEcCtD
Phenylpropanolamine—ADRA2A—adrenal gland—obesity	8.03e-05	0.0124	CbGeAlD
Phenylpropanolamine—Constipation—Sibutramine—obesity	7.82e-05	0.0022	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Orlistat—obesity	7.79e-05	0.00219	CcSEcCtD
Phenylpropanolamine—Tachycardia—Bupropion—obesity	7.78e-05	0.00219	CcSEcCtD
Phenylpropanolamine—CYP1A2—endocrine gland—obesity	7.57e-05	0.0117	CbGeAlD
Phenylpropanolamine—Feeling abnormal—Sibutramine—obesity	7.54e-05	0.00212	CcSEcCtD
Phenylpropanolamine—Hypotension—Bupropion—obesity	7.45e-05	0.00209	CcSEcCtD
Phenylpropanolamine—Insomnia—Bupropion—obesity	7.21e-05	0.00203	CcSEcCtD
Phenylpropanolamine—Hallucination—Topiramate—obesity	7.11e-05	0.002	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Bupropion—obesity	7.11e-05	0.002	CcSEcCtD
Phenylpropanolamine—Somnolence—Bupropion—obesity	7.09e-05	0.00199	CcSEcCtD
Phenylpropanolamine—ADRA2A—endocrine gland—obesity	6.96e-05	0.0108	CbGeAlD
Phenylpropanolamine—Hypersensitivity—Orlistat—obesity	6.96e-05	0.00196	CcSEcCtD
Phenylpropanolamine—CYP1A2—liver—obesity	6.83e-05	0.0106	CbGeAlD
Phenylpropanolamine—Constipation—Bupropion—obesity	6.82e-05	0.00192	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Sibutramine—obesity	6.74e-05	0.00189	CcSEcCtD
Phenylpropanolamine—Flushing—Topiramate—obesity	6.64e-05	0.00186	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Bupropion—obesity	6.57e-05	0.00185	CcSEcCtD
Phenylpropanolamine—Dizziness—Orlistat—obesity	6.25e-05	0.00176	CcSEcCtD
Phenylpropanolamine—Tension—Topiramate—obesity	6.11e-05	0.00172	CcSEcCtD
Phenylpropanolamine—Dizziness—Sibutramine—obesity	6.05e-05	0.0017	CcSEcCtD
Phenylpropanolamine—Nervousness—Topiramate—obesity	6.04e-05	0.0017	CcSEcCtD
Phenylpropanolamine—Vomiting—Orlistat—obesity	6.01e-05	0.00169	CcSEcCtD
Phenylpropanolamine—Rash—Orlistat—obesity	5.96e-05	0.00167	CcSEcCtD
Phenylpropanolamine—Dermatitis—Orlistat—obesity	5.95e-05	0.00167	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Bupropion—obesity	5.87e-05	0.00165	CcSEcCtD
Phenylpropanolamine—Vision blurred—Topiramate—obesity	5.87e-05	0.00165	CcSEcCtD
Phenylpropanolamine—Tremor—Topiramate—obesity	5.83e-05	0.00164	CcSEcCtD
Phenylpropanolamine—Vomiting—Sibutramine—obesity	5.81e-05	0.00163	CcSEcCtD
Phenylpropanolamine—Rash—Sibutramine—obesity	5.77e-05	0.00162	CcSEcCtD
Phenylpropanolamine—Dermatitis—Sibutramine—obesity	5.76e-05	0.00162	CcSEcCtD
Phenylpropanolamine—Agitation—Topiramate—obesity	5.72e-05	0.00161	CcSEcCtD
Phenylpropanolamine—Ephedrine—BCHE—obesity	5.7e-05	0.0463	CrCbGaD
Phenylpropanolamine—Nausea—Orlistat—obesity	5.61e-05	0.00158	CcSEcCtD
Phenylpropanolamine—Nausea—Sibutramine—obesity	5.43e-05	0.00153	CcSEcCtD
Phenylpropanolamine—Anxiety—Topiramate—obesity	5.28e-05	0.00148	CcSEcCtD
Phenylpropanolamine—Dizziness—Bupropion—obesity	5.27e-05	0.00148	CcSEcCtD
Phenylpropanolamine—Confusional state—Topiramate—obesity	5.12e-05	0.00144	CcSEcCtD
Phenylpropanolamine—Vomiting—Bupropion—obesity	5.07e-05	0.00142	CcSEcCtD
Phenylpropanolamine—Rash—Bupropion—obesity	5.03e-05	0.00141	CcSEcCtD
Phenylpropanolamine—Dermatitis—Bupropion—obesity	5.02e-05	0.00141	CcSEcCtD
Phenylpropanolamine—Tachycardia—Topiramate—obesity	4.96e-05	0.00139	CcSEcCtD
Phenylpropanolamine—Ephedrine—ADRB2—obesity	4.9e-05	0.0398	CrCbGaD
Phenylpropanolamine—Hypotension—Topiramate—obesity	4.75e-05	0.00133	CcSEcCtD
Phenylpropanolamine—Nausea—Bupropion—obesity	4.74e-05	0.00133	CcSEcCtD
Phenylpropanolamine—Insomnia—Topiramate—obesity	4.59e-05	0.00129	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Topiramate—obesity	4.53e-05	0.00127	CcSEcCtD
Phenylpropanolamine—Somnolence—Topiramate—obesity	4.52e-05	0.00127	CcSEcCtD
Phenylpropanolamine—Pseudoephedrine—ADRB1—obesity	4.42e-05	0.0359	CrCbGaD
Phenylpropanolamine—Constipation—Topiramate—obesity	4.34e-05	0.00122	CcSEcCtD
Phenylpropanolamine—Pseudoephedrine—TNF—obesity	4.19e-05	0.0341	CrCbGaD
Phenylpropanolamine—Feeling abnormal—Topiramate—obesity	4.19e-05	0.00118	CcSEcCtD
Phenylpropanolamine—Tranylcypromine—CYP2E1—obesity	4.07e-05	0.033	CrCbGaD
Phenylpropanolamine—Hypersensitivity—Topiramate—obesity	3.74e-05	0.00105	CcSEcCtD
Phenylpropanolamine—Pseudoephedrine—ADRB2—obesity	3.72e-05	0.0302	CrCbGaD
Phenylpropanolamine—Phentermine—SLC6A4—obesity	3.56e-05	0.0289	CrCbGaD
Phenylpropanolamine—Pseudoephedrine—SLC6A4—obesity	3.38e-05	0.0274	CrCbGaD
Phenylpropanolamine—Dizziness—Topiramate—obesity	3.36e-05	0.000944	CcSEcCtD
Phenylpropanolamine—Benzyl alcohol—CYP2E1—obesity	3.29e-05	0.0267	CrCbGaD
Phenylpropanolamine—Vomiting—Topiramate—obesity	3.23e-05	0.000908	CcSEcCtD
Phenylpropanolamine—Rash—Topiramate—obesity	3.2e-05	0.0009	CcSEcCtD
Phenylpropanolamine—Dermatitis—Topiramate—obesity	3.2e-05	0.000899	CcSEcCtD
Phenylpropanolamine—Nausea—Topiramate—obesity	3.02e-05	0.000848	CcSEcCtD
Phenylpropanolamine—Phenelzine—CYP2E1—obesity	2.78e-05	0.0226	CrCbGaD
Phenylpropanolamine—Amphetamine—SLC6A4—obesity	2.74e-05	0.0222	CrCbGaD
Phenylpropanolamine—Amphetamine—DRD2—obesity	2.72e-05	0.0221	CrCbGaD
Phenylpropanolamine—Methamphetamine—SLC6A4—obesity	2.54e-05	0.0206	CrCbGaD
Phenylpropanolamine—ADRA2A—Metabolism—PPARA—obesity	1.1e-06	3.35e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—PIK3CB—obesity	1.1e-06	3.35e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PRKCB—obesity	1.09e-06	3.33e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—F2—obesity	1.09e-06	3.33e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—APOB—obesity	1.09e-06	3.32e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CETP—obesity	1.09e-06	3.31e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CCL2—obesity	1.08e-06	3.3e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—PIK3CA—obesity	1.08e-06	3.3e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—ESR1—obesity	1.08e-06	3.3e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—BAD—obesity	1.08e-06	3.29e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—PIK3CB—obesity	1.08e-06	3.29e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—SDC1—obesity	1.07e-06	3.27e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—F2—obesity	1.07e-06	3.26e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PRKCB—obesity	1.07e-06	3.26e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—PTGS2—obesity	1.07e-06	3.26e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IGF1—obesity	1.07e-06	3.25e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—AKT2—obesity	1.07e-06	3.24e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—AGT—obesity	1.06e-06	3.24e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CCL5—obesity	1.06e-06	3.24e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—BAD—obesity	1.06e-06	3.22e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—AKR1C3—obesity	1.06e-06	3.22e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PIK3CG—obesity	1.05e-06	3.19e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—APOE—obesity	1.04e-06	3.18e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—LPL—obesity	1.04e-06	3.17e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—SCARB1—obesity	1.04e-06	3.17e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IRS1—obesity	1.03e-06	3.15e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—CAV1—obesity	1.03e-06	3.15e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—FOXO1—obesity	1.03e-06	3.15e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PRKCD—obesity	1.03e-06	3.14e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—RPS6KB1—obesity	1.03e-06	3.14e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—APOA1—obesity	1.03e-06	3.14e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—obesity	1.03e-06	3.12e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PIK3CG—obesity	1.02e-06	3.12e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PIK3CD—obesity	1.02e-06	3.12e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—PIK3CB—obesity	1.02e-06	3.11e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—PIK3CA—obesity	1.01e-06	3.09e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—SERPINE1—obesity	1.01e-06	3.08e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—obesity	1.01e-06	3.08e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IRS1—obesity	1.01e-06	3.08e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—HTR2A—obesity	1.01e-06	3.07e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—SREBF1—obesity	1.01e-06	3.07e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—C3—obesity	1.01e-06	3.07e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—POMC—obesity	9.96e-07	3.03e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—INS—obesity	9.91e-07	3.02e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—TYK2—obesity	9.85e-07	3e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GOT2—obesity	9.82e-07	2.99e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—RHOA—obesity	9.76e-07	2.97e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CCL2—obesity	9.75e-07	2.97e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—POMC—obesity	9.75e-07	2.97e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—INS—obesity	9.69e-07	2.95e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—obesity	9.68e-07	2.95e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—NOS3—obesity	9.66e-07	2.94e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PIK3R1—obesity	9.66e-07	2.94e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—FASN—obesity	9.61e-07	2.93e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IRS2—obesity	9.59e-07	2.92e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PRKCD—obesity	9.58e-07	2.92e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IGF1—obesity	9.58e-07	2.92e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—AGT—obesity	9.58e-07	2.92e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—AKT2—obesity	9.58e-07	2.92e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—BCHE—obesity	9.57e-07	2.91e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CCL2—obesity	9.54e-07	2.9e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PIK3CG—obesity	9.41e-07	2.87e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—LEP—obesity	9.38e-07	2.86e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—APOE—obesity	9.38e-07	2.86e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HTR2A—obesity	9.38e-07	2.86e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IGF1—obesity	9.37e-07	2.86e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—AKT2—obesity	9.37e-07	2.85e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—C3—obesity	9.36e-07	2.85e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CAV1—obesity	9.3e-07	2.83e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—APOA1—obesity	9.28e-07	2.83e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CYP2E1—obesity	9.23e-07	2.81e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—PIK3CA—obesity	9.21e-07	2.8e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PIK3CD—obesity	9.2e-07	2.8e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—NQO1—obesity	9.13e-07	2.78e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—PIK3CA—obesity	9.11e-07	2.78e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—SERPINE1—obesity	9.1e-07	2.77e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PPARG—obesity	9.08e-07	2.77e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PIK3CD—obesity	9e-07	2.74e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—ESR1—obesity	8.96e-07	2.73e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—POMC—obesity	8.96e-07	2.73e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—obesity	8.94e-07	2.72e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PIK3CB—obesity	8.92e-07	2.72e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MTOR—obesity	8.92e-07	2.72e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—PIK3CA—obesity	8.91e-07	2.72e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IRS2—obesity	8.91e-07	2.71e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—INS—obesity	8.91e-07	2.71e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—SERPINE1—obesity	8.9e-07	2.71e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—AGT—obesity	8.9e-07	2.71e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—AKT1—obesity	8.86e-07	2.7e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—obesity	8.86e-07	2.7e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TYK2—obesity	8.85e-07	2.7e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—F2—obesity	8.85e-07	2.7e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PRKCB—obesity	8.85e-07	2.7e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—RHOA—obesity	8.78e-07	2.67e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GCG—obesity	8.75e-07	2.67e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—SLC2A4—obesity	8.75e-07	2.67e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—BAD—obesity	8.74e-07	2.66e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—LEP—obesity	8.72e-07	2.66e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—APOE—obesity	8.72e-07	2.66e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PIK3R1—obesity	8.69e-07	2.65e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—NOS3—obesity	8.69e-07	2.65e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TYK2—obesity	8.66e-07	2.64e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CAV1—obesity	8.64e-07	2.63e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CYCS—obesity	8.64e-07	2.63e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—APOA1—obesity	8.62e-07	2.62e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—RHOA—obesity	8.59e-07	2.62e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PIK3R1—obesity	8.5e-07	2.59e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—NOS3—obesity	8.5e-07	2.59e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GGT1—obesity	8.47e-07	2.58e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GOT1—obesity	8.47e-07	2.58e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PIK3CG—obesity	8.47e-07	2.58e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IRS1—obesity	8.37e-07	2.55e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—NCOA1—obesity	8.35e-07	2.54e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—ESR1—obesity	8.32e-07	2.54e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—AKT1—obesity	8.28e-07	2.52e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—PIK3CA—obesity	8.28e-07	2.52e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PIK3CD—obesity	8.27e-07	2.52e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CYP19A1—obesity	8.23e-07	2.51e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—STK11—obesity	8.23e-07	2.51e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—F2—obesity	8.22e-07	2.5e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PRKCB—obesity	8.22e-07	2.5e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—ALB—obesity	8.17e-07	2.49e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—IL6—obesity	8.15e-07	2.48e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—BAD—obesity	8.12e-07	2.47e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—PIK3CA—obesity	8.1e-07	2.47e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—POMC—obesity	8.06e-07	2.46e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PIK3CB—obesity	8.02e-07	2.44e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MTOR—obesity	8.02e-07	2.44e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—INS—obesity	8.02e-07	2.44e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CCL2—obesity	7.89e-07	2.4e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PIK3CG—obesity	7.87e-07	2.4e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MTOR—obesity	7.84e-07	2.39e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PIK3CB—obesity	7.84e-07	2.39e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PIK3R1—obesity	7.81e-07	2.38e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—NOS3—obesity	7.81e-07	2.38e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IRS1—obesity	7.78e-07	2.37e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IGF1—obesity	7.75e-07	2.36e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MMP9—obesity	7.75e-07	2.36e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—AKT2—obesity	7.75e-07	2.36e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—COMT—obesity	7.65e-07	2.33e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GNB3—obesity	7.54e-07	2.3e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PPARGC1A—obesity	7.54e-07	2.3e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MAPK8—obesity	7.54e-07	2.3e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—AKT1—obesity	7.52e-07	2.29e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—HMOX1—obesity	7.51e-07	2.29e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—POMC—obesity	7.49e-07	2.28e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—INS—obesity	7.45e-07	2.27e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—AKT1—obesity	7.44e-07	2.27e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PIK3CD—obesity	7.44e-07	2.27e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—PIK3CA—obesity	7.37e-07	2.25e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—SERPINE1—obesity	7.36e-07	2.24e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GNAS—obesity	7.34e-07	2.24e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—IL6—obesity	7.33e-07	2.23e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CCL2—obesity	7.33e-07	2.23e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—AKT1—obesity	7.28e-07	2.22e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PIK3CB—obesity	7.21e-07	2.2e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IGF1—obesity	7.2e-07	2.19e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—AKT2—obesity	7.2e-07	2.19e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—APOB—obesity	7.19e-07	2.19e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—IL6—obesity	7.17e-07	2.18e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TYK2—obesity	7.16e-07	2.18e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PTGS2—obesity	7.14e-07	2.18e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—RHOA—obesity	7.1e-07	2.16e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PIK3R1—obesity	7.03e-07	2.14e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NOS3—obesity	7.03e-07	2.14e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MMP9—obesity	6.97e-07	2.12e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PIK3CD—obesity	6.92e-07	2.11e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—STAT3—obesity	6.89e-07	2.1e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—LPL—obesity	6.87e-07	2.09e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—PIK3CA—obesity	6.85e-07	2.09e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—SERPINE1—obesity	6.84e-07	2.08e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MMP9—obesity	6.82e-07	2.08e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MAPK8—obesity	6.78e-07	2.06e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—AKT1—obesity	6.76e-07	2.06e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GPX1—obesity	6.7e-07	2.04e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—PIK3CA—obesity	6.7e-07	2.04e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TYK2—obesity	6.65e-07	2.03e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MAPK8—obesity	6.63e-07	2.02e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—AKT1—obesity	6.61e-07	2.01e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—RHOA—obesity	6.6e-07	2.01e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—PIK3CA—obesity	6.58e-07	2e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PIK3R1—obesity	6.53e-07	1.99e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NOS3—obesity	6.53e-07	1.99e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CD36—obesity	6.52e-07	1.99e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PIK3CB—obesity	6.49e-07	1.98e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MTOR—obesity	6.49e-07	1.98e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MYC—obesity	6.41e-07	1.95e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—TGFB1—obesity	6.39e-07	1.95e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—PIK3CA—obesity	6.22e-07	1.89e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—STAT3—obesity	6.2e-07	1.89e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—MTHFR—obesity	6.18e-07	1.88e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PPARA—obesity	6.07e-07	1.85e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—STAT3—obesity	6.06e-07	1.85e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MTOR—obesity	6.03e-07	1.84e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PIK3CB—obesity	6.03e-07	1.84e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—AKT1—obesity	6.02e-07	1.83e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—IL6—obesity	5.93e-07	1.81e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—AGT—obesity	5.87e-07	1.79e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MYC—obesity	5.76e-07	1.75e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—APOE—obesity	5.76e-07	1.75e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TGFB1—obesity	5.74e-07	1.75e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CAV1—obesity	5.7e-07	1.74e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—APOA1—obesity	5.69e-07	1.73e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MMP9—obesity	5.64e-07	1.72e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MYC—obesity	5.63e-07	1.72e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TGFB1—obesity	5.62e-07	1.71e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—AKT1—obesity	5.6e-07	1.7e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—IL6—obesity	5.51e-07	1.68e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MAPK8—obesity	5.49e-07	1.67e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—AKT1—obesity	5.47e-07	1.67e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—obesity	5.45e-07	1.66e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PIK3CA—obesity	5.44e-07	1.66e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—AKT1—obesity	5.37e-07	1.64e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MMP9—obesity	5.24e-07	1.6e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PIK3CG—obesity	5.19e-07	1.58e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MAPK8—obesity	5.1e-07	1.55e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—AKT1—obesity	5.08e-07	1.55e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—STAT3—obesity	5.01e-07	1.53e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PPARG—obesity	5.01e-07	1.53e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—POMC—obesity	4.94e-07	1.51e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—INS—obesity	4.92e-07	1.5e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PIK3CA—obesity	4.89e-07	1.49e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IL6—obesity	4.82e-07	1.47e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PIK3CA—obesity	4.78e-07	1.46e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MYC—obesity	4.66e-07	1.42e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—STAT3—obesity	4.66e-07	1.42e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TGFB1—obesity	4.65e-07	1.42e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PIK3CD—obesity	4.57e-07	1.39e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ALB—obesity	4.51e-07	1.37e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—AKT1—obesity	4.44e-07	1.35e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PIK3CA—obesity	4.4e-07	1.34e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MYC—obesity	4.33e-07	1.32e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IL6—obesity	4.33e-07	1.32e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TGFB1—obesity	4.32e-07	1.32e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PIK3R1—obesity	4.31e-07	1.31e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—NOS3—obesity	4.31e-07	1.31e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IL6—obesity	4.23e-07	1.29e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—AKT1—obesity	3.99e-07	1.22e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PIK3CB—obesity	3.98e-07	1.21e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PIK3CA—obesity	3.96e-07	1.2e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PTGS2—obesity	3.94e-07	1.2e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—AKT1—obesity	3.91e-07	1.19e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PIK3CA—obesity	3.68e-07	1.12e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—AKT1—obesity	3.59e-07	1.09e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IL6—obesity	3.5e-07	1.07e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IL6—obesity	3.25e-07	9.91e-06	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—AKT1—obesity	3.23e-07	9.84e-06	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—AKT1—obesity	3e-07	9.14e-06	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PIK3CA—obesity	2.43e-07	7.39e-06	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—AKT1—obesity	1.98e-07	6.04e-06	CbGpPWpGaD
